Bayer ’ s Drug Failed to Improve Mesothelioma Survival

Drug manufacturers announced disappointing ends recently to two different clinical trials involving pleural mesothelioma, dampening earlier enthusiasm over the promise of immunotherapy. Anetumab ravtansine, manufactured by Bayer, and tremelimumab, from drugmaker AstraZeneca, failed an effectiveness test as a stand-alone, second-line treatment for mesothelioma, according to both manufacturers. “Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, an executive vice president at Bayer. Although trial officials have not released their results, LaCaze confirmed the primary endpoint of progression-free survival was not met. Researchers are studying anetumab ravtansine (BAY 949343) with six different types of cancer, while still showing effectiveness in combination with other drugs for treating mesothelioma. Tremelimumab Study Results Tremelimumab is an immunotherapy agent created with human antibodies and has the ability to unmask the cancer cells, allowing a patient’s own immune system to attack. While it has shown effectiveness with non-small cell lung cancer, it did not improve survival in a large, multicenter mesothelioma trial. Although the trial was suddenly stopped in 2016, The Lancet Oncology in July published results of the phase II trial, which involved 105 centers across 19 countries. It included 20 cancer centers within the U.S. The trial originally launched in 2013...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: anetumab ravtansine astrazeneca cancer drug bayer cancer drug bayer mesothelioma drug mesothelioma clinical trials tremelimumab Source Type: news

Related Links:

AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm &neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing. Most of the company&rsq...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Alphatec Boston Scientific Hologic ICON plc Integra LifeSciences NovoCure Orthofix SeaSpine Source Type: news
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Every year, mesothelioma specialists and researchers make strides to advance the standard of care, improve treatment strategies and develop new diagnostic practices. Mesothelioma remains a rare cancer, with an estimated 3,000 people diagnosed each year in the U.S., but the fight to find a cure only grows stronger. And while researchers are busy finding breakthroughs in care, advocates are hard at work campaigning for a ban on asbestos, the main cause of mesothelioma. This was a memorable year on both fronts. Immunotherapy continues to be the hot topic among emerging treatments. Drugs such as pembrolizumab (Keytruda) and ni...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: canada asbestos ban Food and Drug Administration Furthering Asbestos Claims Transparency Act keytruda Medical marijuana mesothelioma mesothelioma vaccine Opdivo Scott Pruitt talcum powder lawsuit yervoy Source Type: news
A leading biopharmaceutical company has halted a once-promising mesothelioma clinical trial involving CRS-207 — a listeria-based cancer vaccine — citing efficacy and financial concerns. The phase II trial was designed to test the effectiveness and safety of CRS-207 when used in combination with pembrolizumab (Keytruda), a drug already proven effective with non-small cell lung cancer. The trial, which began earlier this year, was being conducted at eight prominent cancer centers across the United States. It was funded by Aduro Biotech Inc., based in Berkley, California. “This was not the news everyone had ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center Aduro Biotech Cleveland Clinic CRS-207 H. Lee Moffitt Cancer Center keytruda Listeria virus Mayo Clinic mesothelioma immunotherapy Natalie Sacks NIH National Cancer Institute pembrolizumab Perlmutter Cancer C Source Type: news
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. &ld...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news
More News: Asbestosis | AstraZeneca | Baylor College of Medicine | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Immunotherapy | Italy Health | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Study